Antares Pharma (ATRS) Reports In-Line Q2 EPS
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Antares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $11 million.
For earnings history and earnings-related data on Antares Pharma (ATRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald's (MCD) Tops Q4 EPS by 3c
- Cynosure (CYNO) Could Fetch $60+ Per Share In Sale - Northland Capital
- Aptose Bio (APTO) to Prioritize Development of CG'806 and Temporarily Delay Clinical Activities with APTO-253
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!